Multiclinic evaluation of the antihypertensive effect of a methyldopa, hydrochlorothiazine, and amiloride combination.
A multiclinic, double-blind, randomized study in 361 patients with essential hypertension compared Aldoretic, (Merck & Co., Inc., New Jersey), a combination of methyldopa, hydrochlorothiazide, and amiloride with the combination of hydrochlorothiazide and amiloride and with methyldopa alone. At the end of week 12, the proportion of patients who were classified as normotensive (diastolic less than or equal to 90 mm Hg) was 61% in the group treated with Aldoretic, which was statistically significantly greater than the 48% in the hydrochlorothiazide/amiloride group and the 35% in the methyldopa group.
D000328:Adult; D000368:Aged; D000584:Amiloride / Q000627:therapeutic use*; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011719:Pyrazines / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors
D004338:Drug Combinations; D011719:Pyrazines; D006852:Hydrochlorothiazide; D008750:Methyldopa; D000584:Amiloride; D011188:Potassium